COPD Special Report: The Year in Review

Slideshow

New GOLD guidelines, strategies, and challenges highlighted the key developments for primary care physicians in 2019.

Related Content
Untreated Depression, Anxiety Worsen COPD Outcomes: Daily Dose / image credit: ©New Africa/AdobeStock

Untreated Depression, Anxiety Worsen COPD Outcomes: Daily Dose

Sydney Jennings
April 21st 2025
Article

Your daily dose of the clinical news you may have missed.

Depression, Anxiety Underrecognized and Undertreated in COPD, Increasing Disease Burden

Depression, Anxiety Underrecognized and Undertreated in COPD, Increasing Disease Burden

Grace Halsey
March 27th 2025
Article

A new analysis reveals significant gaps in diagnosis of and treatment for psychiatric disorders in adults with COPD and calls for larger, longitudinal studies.

Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose / image credit: ©New Africa/AdobeStock

Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose

Sydney Jennings
March 24th 2025
Article

Your daily dose of the clinical news you may have missed.

Dupilumab Found Beneficial in COPD with Type 2 Inflammation: Daily Dose / image credit: ©New Africa/AdobeStock

Dupilumab Found Beneficial in COPD with Type 2 Inflammation: Daily Dose

Sydney Jennings
March 20th 2025
Article

Your daily dose of the clinical news you may have missed.

FDA Approves Omlyclo as First Interchangeable Omalizumab Biosimilar

FDA Approves Omlyclo as First Interchangeable Omalizumab Biosimilar

Patient Care Editorial Staff
March 10th 2025
Article

Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.

Dupilumab Shows Efficacy and Safety in COPD With Type 2 Inflammation: AAAAI 2025

Dupilumab Shows Efficacy and Safety in COPD With Type 2 Inflammation: AAAAI 2025

Patient Care Editorial Staff
March 6th 2025
Article

Investigators concluded that dupilumab reduced exacerbation rates, improved lung function, and decreased systemic corticosteroid use in patients with COPD driven by type 2 inflammation.

© 2025 MJH Life Sciences

All rights reserved.